×
About 9,380 results

ALLMedicine™ Myelodysplastic Syndromes Center

Research & Reviews  2,826 results

Natural History and Biospecimen Acquisition for Myelodysplastic Syndromes
https://clinicaltrials.gov/ct2/show/NCT05350748

Aug 5th, 2022 - Background: Myelodysplastic syndromes (MDS) are heterogenous stem cell disorders characterized by ineffective hematopoiesis resulting in cellular dysplasia, peripheral cytopenias, and increased risk for transformation to acute myeloid leukemia (AM...

BMS-986253 in Myelodysplastic Syndromes
https://clinicaltrials.gov/ct2/show/NCT05148234

Aug 5th, 2022 - Background: The myelodysplastic syndromes (MDS) are a group of clonal bone marrow neoplasms characterized by ineffective hematopoiesis, cytopenia, and high risk for transformation to acute myeloid leukemia (AML). MDS is primarily a disease of the ...

A Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)
https://clinicaltrials.gov/ct2/show/NCT05490446

Aug 5th, 2022 - This purpose of this study is to establish proof of concept of AG-946 in participants with LR-MDS in Phase 2a and to compare the effect of AG-946 versus placebo and to detect a dose response for erythroid response in participants with LR-MDS in Ph...

Phase Ib study of eltrombopag and azacitidine in patients with high-risk myelodysplasti...
https://doi.org/10.1111/bjh.18389
British Journal of Haematology; Sternberg A, Boucher R et. al.

Aug 4th, 2022 - Treating adverse risk myelodysplastic syndromes with azacitidine exacerbates thrombocytopenia. We report a study of eltrombopag in combination with azacitidine using a 3 + 3 cohort design. Patients with baseline platelets of <150 × 109 /l received...

5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT03366116

Aug 4th, 2022 - Background: Methylation-mediated silencing of genes is an epigenetic mechanism implicated in carcinogenesis; agents that inhibit this mechanism are of clinical interest because of their potential to re-activate silenced tumor suppressor genes. Two...

see more →

Guidelines  12 results

Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment a...
https://doi.org/10.1016/j.annonc.2020.11.002
Annals of Oncology : Official Journal of the European Soc... Fenaux P, Haase D et. al.

Nov 23rd, 2020 - Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†☆.|2020|Fenaux P,Haase D,Santini V,Sanz GF,Platzbecker U,|

Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH...
https://doi.org/10.1200/JCO.18.02142
Journal of Clinical Oncology : Official Journal of the Am... Bohlius J, Bohlke K et. al.

Apr 11th, 2019 - To update the American Society of Clinical Oncology (ASCO)/American Society of Hematology (ASH) recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients with cancer. PubMed and the Cochrane Library were searched for randomiz...

Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2017.0007
Journal of the National Comprehensive Cancer Network : JN... Greenberg PL, Stone RM et. al.

Jan 4th, 2017 - The myelodysplastic syndromes (MDS) comprise a heterogenous group of myeloid disorders with a highly variable disease course. Diagnostic criteria to better stratify patients with MDS continue to evolve, based on morphology, cytogenetics, and the p...

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3811170
Blood Malcovati L, Hellström-Lindberg E et. al.

Aug 28th, 2013 - Within the myelodysplastic syndrome (MDS) work package of the European LeukemiaNet, an Expert Panel was selected according to the framework elements of the National Institutes of Health Consensus Development Program. A systematic review of the lit...

Myelodysplastic syndromes: clinical practice guidelines in oncology.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4000017
Journal of the National Comprehensive Cancer Network : JN... Greenberg PL, Attar E et. al.

Jul 13th, 2013 - The myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal hematopoietic disorders characterized by cytopenias, dysplasia in one or more myeloid lineages, and the potential for development of acute myeloid leukemia. These disord...

see more →

Drugs  38 results see all →

Clinicaltrials.gov  463 results

BMS-986253 in Myelodysplastic Syndromes
https://clinicaltrials.gov/ct2/show/NCT05148234

Aug 5th, 2022 - Background: The myelodysplastic syndromes (MDS) are a group of clonal bone marrow neoplasms characterized by ineffective hematopoiesis, cytopenia, and high risk for transformation to acute myeloid leukemia (AML). MDS is primarily a disease of the ...

A Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)
https://clinicaltrials.gov/ct2/show/NCT05490446

Aug 5th, 2022 - This purpose of this study is to establish proof of concept of AG-946 in participants with LR-MDS in Phase 2a and to compare the effect of AG-946 versus placebo and to detect a dose response for erythroid response in participants with LR-MDS in Ph...

Natural History and Biospecimen Acquisition for Myelodysplastic Syndromes
https://clinicaltrials.gov/ct2/show/NCT05350748

Aug 5th, 2022 - Background: Myelodysplastic syndromes (MDS) are heterogenous stem cell disorders characterized by ineffective hematopoiesis resulting in cellular dysplasia, peripheral cytopenias, and increased risk for transformation to acute myeloid leukemia (AM...

5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT03366116

Aug 4th, 2022 - Background: Methylation-mediated silencing of genes is an epigenetic mechanism implicated in carcinogenesis; agents that inhibit this mechanism are of clinical interest because of their potential to re-activate silenced tumor suppressor genes. Two...

Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes
https://clinicaltrials.gov/ct2/show/NCT00899223

Aug 3rd, 2022 - The objective of the study is to collect and store specimens from every newly diagnosed patient with acute or chronic leukemia or myelodysplastic syndrome (MDS) who are entered on a CALGB protocol for previously untreated patients. Bone marrow asp...

see more →

News  410 results

Yale Scientists Discover a New Pathogenic Mechanism in Hematological Malignancies
https://www.onclive.com/view/yale-scientists-discover-a-new-pathogenic-mechanism-in-hematological-malignancies

Apr 22nd, 2022 - Scientists at Yale Cancer Center have discovered new consequences of specific gene mutations that play a role in the development of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Approximately half the patients diagnosed with MD...

Treosulfan-Based Conditioning Improves Survival in Elderly, Comorbid Patients With AML
https://www.onclive.com/view/treosulfan-based-conditioning-improves-survival-in-elderly-comorbid-patients-with-aml

Apr 15th, 2022 - Treatment with a treosulfan-based conditioning regimen led to a superior event-free and overall survival (OS) compared with busulfan-based conditioning in patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transpla...

BRCA, HRD Testing Are Essential in Up-front Advanced Ovarian Cancer Management
https://www.onclive.com/view/brca-hrd-testing-are-essential-in-up-front-advanced-ovarian-cancer-management

Mar 1st, 2022 - The first decision in newly diagnosed, advanced ovarian cancer is whether to pursue primary debulking or neoadjuvant chemotherapy, determined in part by the presence of pleural effusion, significant ascites, and diffusely metastatic disease. Howev...

FDA Grants Orphan Drug Designation to Eltanexor for Myelodysplastic Syndromes
https://www.onclive.com/view/fda-grants-orphan-drug-designation-to-eltanexor-for-myelodysplastic-syndromes

Feb 28th, 2022 - The FDA has granted an orphan drug designation to eltanexor (KPT-8602), an investigational novel SINE compound, as a potential therapeutic option for patients with myelodysplastic syndromes (MDS), according to an announcement from Karyopharm Thera...

Oral Decitabine Plus Cedazuridine Combo Shows Promise in Lower-Risk MDS
https://www.onclive.com/view/oral-decitabine-plus-cedazuridine-combo-shows-promise-in-lower-risk-mds

Feb 28th, 2022 - The combination of oral decitabine and cedazuridine (Inqovi) was well tolerated and provided potentially promising outcomes in patients with lower-risk myelodysplastic syndromes (MDS), according to results from the phase 3 ASCERTAIN trial (NCT0330...

see more →

Patient Education  3 results see all →